Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe

Other authors

Institut Català de la Salut

[Vives J] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Teràpia Cellular, Banc de Sang i Teixits (BST), Edifici Dr. Frederic Duran i Jordà, Barcelona, Spain. Grup de Recerca d’Enginyeria Tissular Musculoesquelètica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Advanced Therapy Network (RICORS TERAV), Instituto de Salud Carlos III ((ISCIII), Madrid, Spain. [Sánchez-Guijo F] Spanish Advanced Therapy Network (RICORS TERAV), Instituto de Salud Carlos III ((ISCIII), Madrid, Spain. Department of Medicine, University of Salamanca, Salamanca, Spain. Cell Therapy Area & Haematology Department, Instituto de Investigación Biomédica de Salamanca, University Hospital of Salamanca, Salamanca, Spain. [Gnecchi M] Cell Therapy Area & Haematology Department, Instituto de Investigación Biomédica de Salamanca, University Hospital of Salamanca, Salamanca, Spain. Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy. Department of Cardiothoracic and Vascular Sciences, Translational Cardiology Unit, Fondazione IRCCS, Policlinico San Matteo, Pavia, Italy. [Zwaginga JJ] Department of Hematology, LUMC, Leiden, the Netherlands

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-10-02T12:46:36Z

2023-10-02T12:46:36Z

2023-10



Abstract

Advanced therapy medicinal products; Career development; Training


Medicamentos de terapia avanzada; Desarrollo profesional; Formación


Medicaments de teràpia avançada; Desenvolupament professional; Formació


The development and production of cell gene and tissue (CGT)-based therapies requires a specialized workforce. Entering the CGT arena is complex because it involves different scientific and biomedical aspects (e.g., immunology, stem cell biology and transplantation), as well as knowledge of regulatory affairs and compliance with pharmaceutical quality standards. Currently, both industry and academia are facing a worldwide workforce shortage, whereas only a handful of educational and training initiatives specifically address the peculiarities of CGT product development, the procurement of substances of human origin, the manufacturing process itself and clinical monitoring and biovigilance. The training offered by traditional Master's and PhD programs is not suited for training a skilled workforce ready to enter the increasingly fast-growing CGT field. Indeed, typically these programs are of long duration and only partially cover the required competencies, whereas the demand for a specialized workforce relentlessly increases. In this paper, we (i) present and discuss our understanding of the roots of current growth acceleration of the CGT field; (ii) anticipate future workforce needs due to the expected increase of marketed CGT-based therapies and (iii) evaluate potential solutions that seek to adapt, develop and implement current educational and training initiatives. Importantly for these solutions, we call for scientific societies, such as the International Society for Cell & Gene Therapy, to play a more active role and act as catalysers for new initiatives, building bridges between academia and Industry to establish effective educational and training programs that will engage and prepare a new generation of qualified professionals for entry into the CGT field.

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

Cytotherapy;25(10)

https://doi.org/10.1016/j.jcyt.2023.06.006

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)